ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

BioNTech shores up vaccine supply chain

by Michael McCoy
September 19, 2020 | APPEARED IN VOLUME 98, ISSUE 36

 

BioNTech is taking steps to manufacture BNT162b2, the COVID-19 vaccine it is developing with Pfizer. The German firm has signed a deal to acquire Novartis’s biologic drug production facility in Marburg, Germany, giving it capacity to make up to 750 million vaccine doses a year. It also struck an agreement for the contract manufacturer Siegfried to fill and package the vaccine at its site in Hameln, Germany. BioNTech is getting about $440 million from the German government to expand manufacturing in Germany.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment